Anti-JC virus antibody testing for natalizumab-induced progressive multifocal leukoencephalopathy: Where are we and where should we go?

Abstract

Get full access to this article

View all access options for this article.

References

Dahlhaus

Hoepner

Chan

. Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients. J Neurol Neurosurg Psychiatry 2013; 84: 1068–1074.

Bloomgren

Richman

Hotermans

. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012; 366: 1870–1880.

Gorelik

Lerner

Bixler

. Anti-JC virus antibodies: Implications for PML risk stratification. Ann Neurol. 2010; 68: 295–303.

Trampe

Hemmelmann

Stroet

. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology 2012; 78: 1736–1742.

Lee

Plavina

Castro

. A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification. J Clin Virol 2013; 57: 141–146.

Outteryck

Zéphir

Salleron

. JC-virus seroconversion in multiple sclerosis patients receiving natalizumab. Mult Scler. [Epub ahead of print].

Bozic

Richman

Plavina

. Anti-John Cunningham virus antibody prevalence in multiple sclerosis patients: Baseline results of STRATIFY-1. Ann Neurol 2011; 70: 742–750.

Warnke

Ramanujam

Plavina

. Changes to anti-JCV antibody levels in a Swedish national MS cohort. J Neurol Neurosurg Psychiatry 2013; 84: 1199–1205.

Plavina

Subramanyam

Bloomgren

. Anti-JCV antibody index further defines PML risk in natalizumab-treated MS patients. The 27th Annual Meeting of the Consortium of Multiple Sclerosis Centers 2013. May 29 – June 1, 2013., Orlando, Florida, USA.

10.

Warnke

von Geldon

Markwerth

. The CSF JCV antibody index for diagnosis of natalizumab-associated PML. Ann Neurol 2014. Apr 11. doi: 10.1002/ana.24153. [Epub ahead of print].